Literature DB >> 18606915

The impact of prevention on reducing the burden of cardiovascular disease.

Richard Kahn1, Rose Marie Robertson, Robert Smith, David Eddy.   

Abstract

OBJECTIVE: Cardiovascular disease (CVD) is prevalent and expensive. While many interventions are recommended to prevent CVD, the potential effects of a comprehensive set of prevention activities on CVD morbidity, mortality, and costs have never been evaluated. We therefore determined the effects of 11 nationally recommended prevention activities on CVD-related morbidity, mortality, and costs in the United States. RESEARCH DESIGN AND METHODS: We used person-specific data from a representative sample of the US population (National Health and Nutrition Education Survey IV) to determine the number and characteristics of adults aged 20-80 years in the United States today who are candidates for different prevention activities related to CVD. We used the Archimedes model to create a simulated population that matched the real US population, person by person. We then used the model to simulate a series of clinical trials that examined the effects over the next 30 years of applying each prevention activity one by one, or altogether, to those who are candidates for the various activities and compared the health outcomes, quality of life, and direct medical costs to current levels of prevention and care. We did this under two sets of assumptions about performance and compliance: 100% success for each activity and lower levels of success considered aggressive but still feasible.
RESULTS: Approximately 78% of adults aged 20-80 years alive today in the United States are candidates for at least one prevention activity. If everyone received the activities for which they are eligible, myocardial infarctions and strokes would be reduced by 63% and 31%, respectively. If more feasible levels of performance are assumed, myocardial infarctions and strokes would be reduced 36% and 20%, respectively. Implementation of all prevention activities would add approximately 221 million life-years and 244 million quality-adjusted life-years to the US adult population over the coming 30 years, or an average of 1.3 years of life expectancy for all adults. Of the specific prevention activities, the greatest benefits to the US population come from providing aspirin to high-risk individuals, controlling pre-diabetes, weight reduction in obese individuals, lowering blood pressure in people with diabetes, and lowering LDL cholesterol in people with existing coronary artery disease (CAD). As currently delivered and at current prices, most prevention activities are expensive when considering direct medical costs; smoking cessation is the only prevention strategy that is cost-saving over 30 years.
CONCLUSIONS: Aggressive application of nationally recommended prevention activities could prevent a high proportion of the CAD events and strokes that are otherwise expected to occur in adults in the United States today. However, as they are currently delivered, most of the prevention activities will substantially increase costs. If preventive strategies are to achieve their full potential, ways must be found to reduce the costs and deliver prevention activities more efficiently.

Entities:  

Mesh:

Year:  2008        PMID: 18606915     DOI: 10.1161/CIRCULATIONAHA.108.190186

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  71 in total

1.  [Primary prevention of coronary artery disease: is there a role for risk scores?].

Authors:  H Gohlke
Journal:  Herz       Date:  2012-02       Impact factor: 1.443

2.  Guidelines: we'll always need them, we sometimes dislike them, and we have to make them better.

Authors:  R Kahn
Journal:  Diabetologia       Date:  2010-08-25       Impact factor: 10.122

3.  Analyzing national health reform strategies with a dynamic simulation model.

Authors:  Bobby Milstein; Jack Homer; Gary Hirsch
Journal:  Am J Public Health       Date:  2010-03-18       Impact factor: 9.308

Review 4.  What is the future of stroke prevention?: debate: polypill versus personalized risk factor modification.

Authors:  Walter N Kernan; Lenore J Launer; Larry B Goldstein
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

Review 5.  Benefits and pitfalls of cardiovascular medication in seniors.

Authors:  Hana Matejovska Kubesova; Pavel Weber; Hana Meluzinova; Katarina Bielakova; Jan Matejovsky
Journal:  Wien Klin Wochenschr       Date:  2013-07-12       Impact factor: 1.704

6.  Cardiovascular risk factor modification among high-risk patients: Do pharmacists play a role?

Authors:  Jeffrey Chow; Tammy J Bungard
Journal:  Can Pharm J (Ott)       Date:  2013-09

Review 7.  Safety of nortriptyline at equivalent therapeutic doses for smoking cessation: a systematic review and meta-analysis.

Authors:  Teerapon Dhippayom; Nathorn Chaiyakunapruk; Thitima Jongchansittho
Journal:  Drug Saf       Date:  2011-03-01       Impact factor: 5.606

8.  Implications of discoveries from genome-wide association studies in current cardiovascular practice.

Authors:  Panniyammakal Jeemon; Kerry Pettigrew; Christopher Sainsbury; Dorairaj Prabhakaran; Sandosh Padmanabhan
Journal:  World J Cardiol       Date:  2011-07-26

9.  Tradeoffs in cardiovascular disease prevention, treatment, and research.

Authors:  George Miller; Matthew Daly; Charles Roehrig
Journal:  Health Care Manag Sci       Date:  2012-10-23

10.  The impact of cardiovascular risk-factor profiles on blood pressure control rates in adults from Canada and the United States.

Authors:  Finlay A McAlister; Cynthia Robitaille; Cathleen Gillespie; Keming Yuan; Deepa P Rao; Steven Grover; Sulan Dai; Helen Johansen; Michel Joffres; Fleetwood Loustalot; Norm Campbell
Journal:  Can J Cardiol       Date:  2013-03-01       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.